Michael Dalager-Pedersen

Michael Dalager-Pedersen

Auto-generated profile, based on publicly available information

Michael Dalager-Pedersen

Department of Infectious Diseases, Aalborg University Hospital , Aalborg

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Circulation
Verified
Journal Article
Closed access
PDF file
MDMichael Dalager-Pedersen
Michael Dalager-Pedersen
MSMette Søgaard
Mette Søgaard
HSHenrik Carl Schønheyder
Henrik Carl Schønheyder
HNHenrik Nielsen
Henrik Nielsen
RTReimar Wernich Thomsen
Reimar Wernich Thomsen
Background—: Infections may trigger acute cardiovascular events, but the risk after community-acquired bacteremia is unknown. We assessed the risk for acute myocardial infarction and ischemic stroke within 1 year of community-acquired bacteremia. Methods and Results—: This population-based cohort study was conducted in Northern Denmark. We included 4389 hospitalized medical patients with positive blood cultures obtained on the day of admission. Patients hospitalized with bacteremia were matched with up to 10 general population controls and up to 5 acutely admitted nonbacteremic controls, matched on age, sex, and calendar time. All incident events of myocardial infarction and stroke during the following 365 days were ascertained from population-based healthcare databases. Multivariable regression analyses were used to assess relative risks with 95% confidence intervals (CIs) for myocardial infarction and stroke among bacteremia patients and their controls. The risk for myocardial infarction or stroke was greatly increased within 30 days of community-acquired bacteremia: 3.6% versus 0.2% among population controls (adjusted relative risk, 20.86; 95% CI, 15.38–28.29) and 1.7% among hospitalized controls (adjusted relative risk, 2.18; 95% CI, 1.80–2.65). The risks for myocardial infarction or stroke remained modestly increased from 31 to 180 days after bacteremia in comparison with population controls (adjusted hazard ratio, 1.64; 95% CI, 1.18–2.27), but not versus hospitalized controls (adjusted hazard ratio, 0.95; 95% CI, 0.69–1.32). No differences in cardiovascular risk were seen after >6 months. Increased 30-day risks were consistently found for a variety of etiologic agents and infectious foci. Conclusions—: Community-acquired bacteremia is associated with increased short-term risk of myocardial infarction and stroke.

1 January 2020 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JBJ. Bodilsen
J. Bodilsen
MDM. Dalager-Pedersen
M. Dalager-Pedersen
DBDiekerik van de Beek
Diekerik van de Beek
MBM.C. Brouwer
M.C. Brouwer
HNH. Nielsen
H. Nielsen

9 August 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JBJacob Bodilsen
Jacob Bodilsen
MDMichael Dalager-Pedersen
Michael Dalager-Pedersen
HSHenrik Carl Schønheyder
Henrik Carl Schønheyder
HNHenrik Nielsen
Henrik Nielsen
Community-acquired bacterial meningitis (CABM) is a life-threatening disease and timing of antibiotic therapy remains crucial. We aimed to analyse the impact of antibiotic timing on the outcome of CABM in a contemporary cohort. We conducted a population-based cohort study based on chart reviews of all adult cases (>16 years of age) of CABM in North Denmark from 1998 to 2014 excluding patients given pre-hospital parenteral antibiotics. We used modified Poisson regression analyses to compute the adjusted risk ratio (adj. RR) with 95 % confidence intervals (CIs) for in-hospital mortality and unfavourable outcome at discharge by time after arrival to hospital to adequate antibiotic therapy. We identified 195 adults with CABM of whom 173 patients were eligible for further analyses. The median door-to-antibiotic time was 2.0 h (interquartile range (IQR) 1.0–5.5). We observed increased adjusted risk ratios for in-hospital mortality of 1.6 (95 % CI 0.8–3.2) and an unfavourable outcome at discharge of 1.5 (95 % CI 1.0–2.2, p = 0.03) when treatment delays exceeded 6 h versus treatment within 2 h of admission. These findings corresponded to adjusted risk ratios of in-hospital mortality of 1.1 per hour of delay (95 % CI 0.8–1.5) and an unfavourable outcome at discharge of 1.1 per hour of delay (95 % CI 1.0–1.3) within the first 6 h of admission. Some patients (31 %) were diagnosed after admission and had more delays in antibiotic therapy and correspondingly increased in-hospital mortality (30 vs 14 %, p = 0.01) and unfavourable outcome (62 vs 37 %, p = 0.002). Delay in antibiotic therapy was associated with unfavourable outcome at discharge.

27 November 2019 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
JBJacob Bodilsen
Jacob Bodilsen
MDMichael Dalager-Pedersen
Michael Dalager-Pedersen
DBDiederik van de Beek
Diederik van de Beek
MBMatthijs C Brouwer
Matthijs C Brouwer
HNHenrik Nielsen
Henrik Nielsen
Background: We aimed to determine the long-term risks of mortality and new-onset epilepsy after brain abscess. Methods: Using nationwide population-based medical registries, we examined all patients with first-time brain abscess in Denmark, 1982–2016. Comparison cohorts individually matched on age, sex, and residence were identified, as were siblings of all study participants. Next, we computed cumulative incidences and hazard rate ratios (HRRs) with 95% confidence intervals of mortality and new-onset epilepsy among study populations. Results: We identified 1384 brain abscess patients (37% females) with a median follow-up time of 5.9 years (interquartile range [IQR] 1.1–14.2). The 1-year, 2–5 year, and 6–30 year mortality of patients after brain abscess was 21%, 16%, and 27% as compared to 1%, 6%, and 20% for population controls. Cox regression analyses adjusted for Charlson comorbidity index score showed 1-year, 2–5 year, and 6–30 year HRRs of 17.5 (13.9–22.0), 2.61 (2.16–3.16), and 1.94 (1.62–2.31). The mortality in brain abscess patients was significantly increased regardless of sex or age group except among subjects 80 years or older, and in both previously healthy individuals and immunocompromised persons. Among the 30-day survivors of brain abscess (median follow-up 7.6 years [IQR 2.2–15.5]), new-onset epilepsy occurred in 32% compared to 2% in matched population controls. Cause-specific Cox regression analysis adjusted for stroke, head trauma, alcohol abuse, and cancer showed 1-year, 2–5 year, and 6–30 year HRRs for new-onset epilepsy of 155 (78.8–304), 37.7 (23.0–59.9), and 8.93 (5.62–14.2). Conclusions: Brain abscess is associated with an increased long-term risk of mortality and new-onset epilepsy for several years after infection.

23 October 2019 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JBJacob Bodilsen
Jacob Bodilsen
MDMichael Dalager-Pedersen
Michael Dalager-Pedersen
DBDiederik van de Beek
Diederik van de Beek
MBMatthijs C Brouwer
Matthijs C Brouwer
HNHenrik Nielsen
Henrik Nielsen
Background: Knowledge on risk factors for brain abscess is limited and relies on single-center cohort studies. Methods: We accessed nationwide medical registries to conduct a population-based, nested case-control study of risk factors for brain abscess. We applied risk-set sampling for the selection of population controls (1:10), who were individually matched by age, sex, and area of residence. Conditional logistic regression was used to compute adjusted odds ratios (aOR) with 95% confidence intervals (CIs). Population-attributable fractions were calculated. Results: We identified 1384 brain abscess patients in Denmark from 1982 through 2016, and 13 839 matched population controls. The median age of patients was 50 years (interquartile range 33–63) and 37% were female. Cases often had Charlson comorbidity scores >2 (16%), compared with controls (3%). Our calculated aORs were 2.15 (95% CI 1.72–2.70) for head trauma; 19.3 (95% CI 14.3–26.0) for neurosurgery; 4.61 (95% CI 3.39–6.26) for dental infections; 2.57 (95% CI 1.71–3.84) for dental surgery; 3.81 (95% CI 3.11–4.67) for ear, nose, and throat infection; 2.85 (95% CI 2.21–3.70) for ear, nose, and throat surgery; 15.6 (95% CI 9.57–25.4) for congenital heart disease; 1.74 (95% CI 1.33–2.29) for diabetes mellitus; 2.22 (95% CI 1.58–3.11) for alcohol abuse; 2.37 (95% CI 1.53–3.68) for liver disease; 2.04 (95% CI 1.30–3.20) for kidney disease and 8.15 (95% CI 3.59–18.5) for lung abscess or bronchiectasis. The aORs were 4.12 (95% CI 3.37–5.04) for solid cancer; 8.77 (95% CI 5.66–13.6) for hematological cancer; 12.0 (95% CI 6.13–23.7) for human immunodeficiency virus; and 5.71 (95% CI 4.22–7.75) for immunomodulating treatments. Population-attributable fractions showed were substantial contributors to the occurrence of brain abscess neurosurgery (12%); solid cancer (11%); ear, nose, and throat infections (7%); and immunomodulating treatments (5%). Conclusions: Important risk factors included neurosurgery; cancer; ear, nose, and throat infections; and immunomodulating treatments.

1 February 2018 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
JBJ. Bodilsen
J. Bodilsen
CBC.T. Brandt
C.T. Brandt
ASA. Sharew
A. Sharew
MDM. Dalager-Pedersen
M. Dalager-Pedersen
TBThomas Benfield
Thomas Benfield
HNH. Nielsen
H. Nielsen